

## Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6990)

**REVISED FORM OF PROXY FOR THE 2023 ANNUAL GENERAL MEETING** TO BE HELD ON JUNE 20, 2024

I/We<sup>(Note 1)</sup>

being the registered holder(s) of <sup>(Note 2)</sup> of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the " <b>Company</b> "), <b>HEREBY APPOINT THE C</b> orf <sup>(Note 3)</sup>	CHAIRMAN OF	ares (the "Share(s)" THE AGM
of (Address)	ling, Sichuan Kelun-Bio ole's Republic of China adjournment thereof)	otech Biopharmaceutica (the "AGM") (and an to vote for me/us and in
ORDINARY RESOLUTIONS For <sup>(Note 4)</sup>	Against <sup>(Note 4)</sup>	Abstain <sup>(Note 4)</sup>
1. To consider and approve the financial accounts report of the Group for the year 2023.		
<ol> <li>To consider and approve the financial budget report of the Group for the year 2024.</li> </ol>		
3. To consider and approve the report of the Board of Directors for the year 2023.		
<ol> <li>To consider and approve the report of the Supervisory Committee for the year 2023.</li> </ol>		
5. To consider and approve the annual report of the Group for the year 2023.		
6. To consider and approve the re-appointment of KPMG as the auditors of the Company for the year 2024, for a term commencing from the date of approval of this resolution until the conclusion of the next annual general meeting of the Company, and to authorize the Board of Directors to determine the specific matters, including but not limited to their remuneration of not more than RMB2,400,000 for the year 2024 before tax, in relation to such appointment.		
<ol> <li>To consider and approve the remuneration of the Directors and Supervisors for the year 2024.</li> </ol>		
8. To consider and approve the annual profit distribution plan of the Company for the year 2023.		
<ol> <li>To consider and approve the acquisition of wealth management products with idle self-owned funds for the year 2024, with the details as set out in the circular of the Company dated May 21, 2024 (the "Original Circular").</li> </ol>		
10. To consider and approve the proposed appointment of Mr. LAI Degui as a non-executive Director of the third session of the Board.		
SPECIAL RESOLUTIONS For <sup>(Note 4)</sup>	Against <sup>(Note 4)</sup>	Abstain <sup>(Note 4)</sup>
11. To consider and approve the grant of a general mandate to the Board to issue Shares and sell Treasury Shares, with the details of the general mandate as set out in the Original Circular.		
12. To consider and approve the grant of a general mandate to the Board to repurchase H Shares, with the details of the general mandate as set out in the Original Circular.		
13. (a) To consider and approve the grant of a specific mandate (the "Subscription Specific Mandate") for a validity period of 12 months from the date of approval at the AGM to issue 4,423,870 new Domestic Share in accordance with the terms and conditions of the Subscription Agreement dated May 8, 2024 and entered into by the Company as issuer and Kelun Pharmaceutical as Subscriber.		
(b) To consider and approve the authorization to the Board and persons authorized by the Board to deal with all matters in relation to the issue of new Domestic Shares under the Subscription Specific Mandate as set out in special resolution 13.		
14. (a) To consider and approve the proposed amendments to the articles of association of the Company as set out in the Original Circular which result from the completion of the Placing (as defined in the Original Circular).		
(b) To consider and approve the proposed amendments to the articles of association of the Company as set out in the Original Circular which will result from the completion of the Subscription (as defined in the Original Circular).		
(c) To consider and approve the proposed amendments to the articles of association of the Company as set out in the supplemental circular of the Company dated May 31, 2024 which result from the resignation of Supervisors.		

day Dated this

Full names(s) and address(es) to be inserted should be in **BLOCK CAPITALS**.

Signature(s)(Note 5):

Notes:

2.

Please insert the number of shares registered in your name(s) and type of shares (domestic shares or H shares) to which this proxy form relates. If no number is inserted, this form of proxy will be deemed to relate to all the shares of the Company registered in your name(s). 3

of the Company registered in your name(s). If any proxy other than the chairman of the AGM is preferred, strike out the words "THE CHAIRMAN OF THE AGM or" and insert the name and address of the proxy desired in the space provided. A shareholder entitled to attend and vote at the AGM may appoint one or more proxies to attend and vote in his stead provided that if more than one proxy is so appointed, the appointment shall specify the number of shares of which each such proxy is so appointed. A proxy need not be a shareholder of the Company but must attend the AGM in person to represent you. Such proxies may only exercise their voting rights in a poll. 4

- is so approduct. A plose need to be a simulation of the company on most match and the Contra place on terpescan you, your provides may only Cetters under forming rights in a point. IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, TICK (./) IN THE RELEVANT BOX BELOW THE BOX MARKED "FORT IF YOU WISH TO VOTE AGAINST A RESOLUTION, TICK (./) IN THE RELEVANT BOX BELOW THE BOX MARKED "AGAINST". IF YOU WISH TO ABSTAIN, TICK (./) IN THE RELEVANT BOX BELOW THE BOX MARKED "ABSTAIN". Any abstain vote will be counted in the total number of voting shares. If no direction is given, your proxy may vote or abstain at his discretion. Your proxy will also be entitled to vote or abstain at his discretion on any resolution properly put to the AGM other than that referred to in the notice convening the AGM. 5
- This proxy form must be signed by you or your atomey duly authorized in writing. In case of a corporation, the same must be executed either under its common seal or under the hand of its director(s) or duly authorized atomey. If the proxy form is signed by an atomey of the shareholder, the power of atomey authorizing that attorney to sign or other authorization document must be notarized. In order to be valid, this form of proxy (the "**Revised Proxy Form**"), together with the power of atomey or other authorizing if any under which it is signed, or a notarially certified copy of such power of atomey or authority, must be completed and returned to the Company's headquarters and principal place of business in the PRC, at No. 666 Xinhua Arenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wangian District, Chengdu, Sichuan Province, the People's Republic of China (for holders of dharses) or the H Share Registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queer's Nead East, Manchai, Hong Kong (for holders of H shares), ont less than 24 hours before the time fixed for holding the AGM or any adjourned meeting thereof should he/she so wish.
- 7 In the case of joint holders of a share, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names static of methods or the Company is respect of the relevant joint holding.

## ANY ALTERATION MADE TO THIS FORM OF PROXY MUST BE INITIALLED BY THE PERSON WHO SIGNS IT.

of 2024

- A shareholder who has not yet lodged the form of proxy dated May 21, 2024 ("Original Proxy Form") with the H Share Registrar is requested to lodge the Revised Proxy Form if he/she/it wishes to appoint proxy(ies) to attend the AGM on his/her behalf. In this case, the Original Proxy Form should not be lodged with the H Share Registrar. 9. 10.
- A shareholder who has already lodged the Original Proxy Form with the Company's H Share Registrar should note that:
  - if no Revised Proxy Form is lodged with the H Share Registrar, the Original Proxy Form will be treated as a valid form of proxy lodged by him/her/it if correctly completed. The proxy so appointed by the shareholder shall be required to vote in such manner as he/she/it may be directed under the Original Proxy Form and, in respect of the resolutions set out in the Supplemental Notice of AGM and the Revised Proxy Form, the proxy will be entitled to vote at his/her/its discretion or to abstain from voting on such resolution. (i)
  - if the Revised Proxy Form is lodged with the H Share Registrar before the Proxy Closing Time, the Revised Proxy Form, if correctly completed, will revoke and supersede the Original Proxy Form previously lodged by the shareholder. (ii)
  - if the Revised Proxy Form is lodged with the H Share Registrar after the Proxy Closing Time, or if lodged before the Proxy Closing Time but is incorrectly completed, the proxy appointment under the Revised Proxy Form will be invalid. The proxy so appointed by the shareholder under the Original Proxy Form, if correctly completed, will be entitled to vote in the manner as mentioned in (i) above as if no Revised Proxy Form was lodged with the H Share Registrar Accordingly, shareholders are advised to complete the Revised Proxy Form carefully and lodge the Revised Proxy Form with the H Share Registrar before the Proxy Closing Time. (iii)
- 11 Reference to time and dates in this form of proxy are to Hong Kong time and dates

## PERSONAL INFORMATION COLLECTION STATEMENT

Your supply of your and your proxy's (or proxies') name(s) and address(es) is on a voluntary has ifs of the purpose of processing your request for the appointment of a proxy (or proxies) and your voting instructions for the AGM of the Company (the "Purposes"). We may transfer your and your proxy's (or proxies') name(s) and address(es) to our agent, contractor, or third party service provider who provides administrative, computer and other services to us for use in connection with the Purposes and to such parties who are authorized by law to request the information or are otherwise relevant for the Purposes is and evaluation and your proxy's (or proxies') name(s) and address(es) to our a evaluation to the Purposes. Such as the crecive the information or are otherwise relevant for the Purposes and no such and your proxy's (or proxies') name(s) and address(es) will be retained for such period as may be necessary to fulfil the Purposes. Request for access to and/or correction of the relevant personal data can be made in accordance with the provisions of the Personal Data (Privacy) Ordinance and any such request should be in writing by either of the following means:

By mail to:

De in Writing by chiere or me ronowing means. Personal Data Privacy Officer Computershare Hong Kong Investor Services Limited 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong

By email to: PrivacyOfficer@computershare.com.hk